US 8591889
Human monoclonal antibodies specific for CD22
granted A61KA61K2039/505A61K38/164
Quick answer
US patent 8591889 (Human monoclonal antibodies specific for CD22) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Nov 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America as Represented by the Secretary of the Department of Health and Human Services
- Grant date
- Tue Nov 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 23
- CPC classes
- A61K, A61K2039/505, A61K38/164, A61K38/45, A61K39/00